News & Events about Nurix Therapeutics Inc.
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurixs two first-in-class BTK degraders in 2023 Clinical data update planned for Nurixs first-in-class CBL-B ...
Globe Newswire
2 months ago
Biomarker results are a positive demonstration of target engagement for this first-in-classCBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix ...
Globe Newswire
2 months ago
Presentations highlight use of Nurixs first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 programSAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing ...
Globe Newswire
3 months ago
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignanciesSAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs ...
Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio? Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio? PR Newswire NEW YORK, Oct. 21, 2022 NEW YORK...